PTM-001-ADC

About PTM Therapeutics

PTM Therapeutics is an early-stage biotech pioneering a novel approach to drug discovery by targeting Post-Translational Modifications (PTMs), which are protein alterations prevalent in disease states. The company has developed a proprietary 'Conditioned Target Discovery Platform' to generate therapeutic antibodies against these targets, with two initial programs focused on inflammatory bowel disease/ulcerative colitis and metastatic colon cancer. Operating as a private, pre-revenue entity, PTM aims to tap into a significant and underexplored area of biology to develop more specific and effective treatments.

Therapeutic Areas